Unigen Pharmaceuticals Enters Into Strategic Research and Product Development Agreement With Primus Pharmaceuticals

Broomfield, CO – April 22, 2003 – Unigen Pharmaceuticals, Inc., a leading research and development facility and supplier of proprietary plant-derived biologically active ingredients to the natural products and pharmaceutical industries, has entered into a strategic research and product development agreement with Primus Pharmaceuticals, Inc. to develop and commercialize prescription products derived from proprietary plant sources. Primus, located in Scottsdale, AZ, is a specialty pharmaceutical company that develops and commercializes patented branded prescription products by marketing principally to Primary Care Physician audiences.

Both companies will leverage their individual strengths and collaborate closely during their 10-year partnership to develop several prescription brands containing patented active ingredients developed by Unigen, and scientifically tested and qualified for the market by Primus. Unigen and Primus will collaborate to develop unique, clinically supported prescription products across a range of therapeutic areas utilizing patented botanical ingredients and delivery systems to serve market segments and particular patient populations with distinctive needs. “We are pleased and excited to work with a company that is an expert in building brands,” commented Unigen’s CEO, Derek Hall. “Primus’ proven management team, with their backgrounds in pharmaceuticals and consumer products, understands how to use patented ingredients and delivery systems to develop prescription products with great market potential.”

J.D. Weir, CEO of Primus, said, “Unigen’s strong scientific research capabilities and worldwide screening system, coupled with its PhytoLogix* technology platform, has produced a plant library comprising hundreds of thousands of isolated compounds and constituents. These categorized compounds result in many proprietary candidates from which Primus and Unigen can develop both novel and compelling products.” He added, “I speak on behalf of all of us here at Primus when I say how much we look forward to such a complementary partnership with Unigen.”

* PhytoLogixTM is one of the world's largest technology information sources for the predictive discovery of active ingredients and constituents derived from ethnomedicinal plants. This resource references historic uses and reduces considerable time from the front end of the research process.

# # #

About Unigen Pharmaceuticals
Unigen Pharmaceuticals, Inc. is a leading natural products research and development facility and proprietary ingredients supplier. The company is dedicated to the discovery of botanically derived therapeutic compounds that address consumer health needs and help improve the quality of human life. Unigen (www.unigenpharma.com), and sister company Aloecorp, are subsidiaries of Univera, Inc. Both companies focus on identifying and studying the unique ingredients of medicinal botanicals (Aloecorp’s focus is on Aloe vera) and then formulating proprietary raw materials for use in cosmeceutical, nutraceutical and pharmaceutical products.

About Primus Pharmaceuticals
Primus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company that develops and commercializes patented branded prescription products in growing market segments served by Primary Care Physicians. The company collaborates on an exclusive basis with a leading pharmaceutical research and development company as well as with a major medical university to license, develop and test proprietary products. In addition, Primus partners with selected established pharmaceutical companies in the national distribution of its products. For more information, contact [email protected].

Susan Westfall, Principal Regan Miles, V.P. – Sales & Marketing
Westfall Communications Unigen Pharmaceuticals, Inc.
303-926-4093 303-438-8666 x11
[email protected] [email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.